|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02877 SHINEWAY PHARM
Nominal 
8.630 +0.010 (+0.116%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 1,652,698 | -20.798% | 3,778,043 | 4,516,538 | 3,950,636 | 3,223,550 |
| Cost of Sales | (459,092) | -10.771% | (946,294) | (1,122,419) | (1,012,322) | (813,214) |
| Gross Profit | 1,193,606 | -24.080% | 2,831,749 | 3,394,119 | 2,938,314 | 2,410,336 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 1,835 | -- | (6,612) | (5,440) | (8,828) | (7,021) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 774,678 | -10.139% | 1,145,721 | 1,240,253 | 917,025 | 720,103 | |
| Taxation | (160,015) | -32.083% | (305,669) | (270,743) | (194,252) | (163,429) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 614,663 | -1.886% | 840,052 | 969,510 | 722,773 | 556,674 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (113,957) | -3.688% | (170,589) | (92,470) | (91,801) | (93,812) |
| Depreciation & Amortisation | 73,935 | -8.358% | 68,735 | 60,233 | 58,686 | 63,661 |
| Directors' Emoluments | -- | -- | 14,122 | 42,317 | 11,849 | 10,319 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 81.000 | -2.410% | 111.000 | 128.000 | 96.000 | 74.000 |
| DPS (cts) | 47.000 | -- | 54.000 | 42.000 | 32.000 | 39.000 |
| Dividend Payout Ratio (%) | 58.025% | -- | 48.649% | 32.813% | 33.333% | 52.703% |
| Cash flow per share ($) | -- | -- | 1.275 | 1.235 | 1.469 | 0.931 |
| NBV per share ($) | 9.443 | -- | 9.029 | 8.506 | 7.718 | 7.136 |
| Remarks: | Real time quote last updated: 02/09/2025 11:35 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 614,663 |
| %Change | -1.886% |
| EPS / (LPS) | RMB 0.810 |
| NBV Per Share (¥) | RMB 9.443 |